FDA launches new mechanism to expedite development of individualized targeted therapies for ultra-rare diseases
February 23, 2026 The U.S. Food and Drug Administration (FDA) announced the publication of draft guidance establishing a new regulatory approach to the development and approval of individualized therapies for patients with ultra-rare diseases.
The document introduces a Plausible Mechanism Framework—a mechanism for generating sufficient evidence of efficacy and safety in situations where randomized controlled trials are not feasible due to extremely small patient numbers.
The draft was developed by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). It focuses on genome editing and RNA-based therapies, including antisense oligonucleotides. The approach is also potentially applicable to other individualized targeted technologies if they directly affect the established molecular cause of the disease.
Which therapies are covered by the approach
The guidance applies to developments that:
• target a specific genetic, cellular, or molecular abnormality;
• are intended to correct or modify the underlying cause of the disease;
• are being developed for extremely small patient populations.
Key outcome criteria
The FDA emphasizes that even with small sample sizes, clinical data must be robust enough to exclude the possibility of chance findings.
Master Protocols and Genomic Editing
Genomic editing is receiving particular attention. Since such technologies are specific to certain DNA sequences, different mutations of the same gene can be combined within a single registration application.
The FDA allows the use of master protocols to evaluate multiple product variations within a single study. With a compelling mechanism of action, new treatment options may be added for patients with mutations not included in the original clinical trial.
Regulatory Significance
The Agency emphasizes its willingness to apply regulatory flexibility while maintaining evidence-based and safety requirements. This new approach is intended to remove barriers associated with the inability to conduct large, randomized trials in ultra-rare diseases.
The Plausible Mechanism Framework is expected to stimulate the development of individualized gene and RNA therapies, accelerate the market entry of innovative solutions, and expand access to potentially life-saving treatments for patients with ultra-rare diseases.
🔗 Draft Guidance (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausibl... for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause” is available for public comment (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausibl...)
The document introduces a Plausible Mechanism Framework—a mechanism for generating sufficient evidence of efficacy and safety in situations where randomized controlled trials are not feasible due to extremely small patient numbers.
The draft was developed by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). It focuses on genome editing and RNA-based therapies, including antisense oligonucleotides. The approach is also potentially applicable to other individualized targeted technologies if they directly affect the established molecular cause of the disease.
Which therapies are covered by the approach
The guidance applies to developments that:
• target a specific genetic, cellular, or molecular abnormality;
• are intended to correct or modify the underlying cause of the disease;
• are being developed for extremely small patient populations.
Key outcome criteria
- Clear identification of the pathogenic abnormality causing the disease.
- Evidence of treatment effect on the underlying cause or key biological pathway.
- Use of well-characterized data natural history of the disease in untreated patients.
- Confirmation of successful targeting or target editing.
- For traditional approval—demonstration of improved clinical outcomes, changes in disease course, or validated biomarkers if they are recognized as predictors of clinical benefit.
The FDA emphasizes that even with small sample sizes, clinical data must be robust enough to exclude the possibility of chance findings.
Master Protocols and Genomic Editing
Genomic editing is receiving particular attention. Since such technologies are specific to certain DNA sequences, different mutations of the same gene can be combined within a single registration application.
The FDA allows the use of master protocols to evaluate multiple product variations within a single study. With a compelling mechanism of action, new treatment options may be added for patients with mutations not included in the original clinical trial.
Regulatory Significance
The Agency emphasizes its willingness to apply regulatory flexibility while maintaining evidence-based and safety requirements. This new approach is intended to remove barriers associated with the inability to conduct large, randomized trials in ultra-rare diseases.
The Plausible Mechanism Framework is expected to stimulate the development of individualized gene and RNA therapies, accelerate the market entry of innovative solutions, and expand access to potentially life-saving treatments for patients with ultra-rare diseases.
🔗 Draft Guidance (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausibl... for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause” is available for public comment (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausibl...)
